Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators
β Scribed by Peter Nygren; Rolf Larsson
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- French
- Weight
- 793 KB
- Volume
- 48
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
β¦ Synopsis
DIFFERENTIAL CYTOTOXIC SENSITIVITY OF HUMAN NORMAL AND TUMOR CELLS 599 TABLE I -CHARACTERISTICS OF THE INVESTIGATED HUMAN CELL TYPES' ~ Cell type Origin Characteristic Type of culture Growth rate in vifro exDreSS,On Pgp, ACHN LO Lloo Fibroblasts Lymphocytes CLL, AML Cells from solid tnmors Kidney adenocarcinoma Acute T-cell lymphoblastic leukemia Vcr-resistant subline from LO Amniotic fluid Healthy blood donors Peripheral-blood samples from patients with leukemia Patients operated on for tumor resection Continuous cell line Doubling time 33 hr No Continuous cell line Doubling time 72 hr No Continuous cell line Doubling time 72 hr Yes Cell line, used at Doubling time 96 hr ND passages 3 to 12 Primary cultures No growth ND Primary cultures No growth ND Primary cultures No growth ND ~ 'Pgp expression accordlng to Nygren and Larsson, 1990.-ND, not done
π SIMILAR VOLUMES
Together with tolerance to killing induced by methylating agents, loss of mismatch repair (MMR) has previously been found to be associated with hypersensitivity to the DNAcross-linking agent 1-(2-chloroethyl)-3-cyclohexyl-nitrosourea(CCNU) in several human tumor cell lines (Aquilina et al., 1998). H
Calcium channel blockers, calmodulin inhibitors, and some other classes of non-related compounds reverse multi-drug resistance. In the present study, we found that several resistance modifiers are more toxic for MDR cells than for the corresponding sensitive parent cells, whereas others show the opp
## Abstract Women approaching menopause increasingly investigate alternatives to hormone replacement therapy. Plant phytoestrogens are being promoted as βnaturalβ alternatives but there is a lack of substantive data to advocate their safe use in breast cancer patients receiving tamoxifen (TAM), or